The aim of this study was to determine the incidence and the clinical and pathological features of gastrointestinal stromal tumors within a nonselected, well-defined Canadian Health Region. A population-based cohort study of all adult patients diagnosed with gastrointestinal stromal tumors was conducted in the Calgary Health Region from April 2000 to March 2004. All charts and pathological specimens were reviewed for clinical, histological, and antigenic features. The age-adjusted and gender-adjusted annual incidence rate was 0.91/105 person-years. There was a trend for increased incidence with routine use of CD117. The only identified risk was advancing age (age ≥50; rate ratio = 4.6; P = .0006). All samples were positive for CD117. At presentation, 19% were at intermediate and 19% were at high risk of becoming malignant, with 14% being overtly metastatic. This is the first North American study to define the incidence and the clinical and pathologic features of gastrointestinal stromal tumors based on current diagnostic criteria.
Kitamura Y., Hirota S., Nishida T.Gastrointestinal stromal tumors (GIST): a model for molecule based diagnosis and treatment of solid tumors. Cancer Sci. 2003; 94:315-320.
2.
Mazur MT, Clark HBGastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507-519.
3.
Kindblom LG, Remotti HE, Aldenborg F., Meis-Klindblom JMGastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal . Am J Pathol. 1998;152:1259-1269.
4.
Yarden Y., Kuang WJ, Yang-Feng T., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6:3341-3351.
5.
Vliagoftis H. , Worobec AS, Metcalfe DDThe proto-oncogene c-kit and c-kit ligand in human disease. J Alleg Clin Immunol. 1997 ;100:435-440.
6.
Huizinga JD, Thuneberg L., Klüppel M., Malysz J., Mikkelsen HB, Bernstein A.W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature. 1995;373:347-349.
7.
Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
8.
Dematteo RP, Heinrich MC, El-Rifai W., Demetri G.Clinical management of gastrointestinal stormal tumors: before and after STI-571 . Hum Pathol. 2002;33:466-477.
9.
Sarlomo-Rikala M., Kovatich AJ, Barusevicius A., Miettinen M.CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34 . Mod Pathol . 1998;11:728-734.
10.
Corless CL, Fletcher JA, Heinrich MCBiology of gastrointestinal stromal tumors. J Clin Onc. 2004;22: 3813-3825.
11.
Fletcher CDM , Berman JJ, Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465.
12.
Miettinen M. , Majidi M., Lasota J.Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38(suppl 5):39S-51S.
13.
Miettinen M. , Lasota J.Gastrointestinal stromal tumors- definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.
14.
Blackstein ME , Dube P., Fletcher JA, et al. Gastrointestinal stromal tumors: etiology, pathology, and clinical management. Can J Gastroenterol. 2004;18(suppl B): 3B-8B.
15.
Rossi CR, Mocellin S., Mencarelli R., et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer. 2003;107:171-176.
16.
Bucher P., Villiger P., Egger JF, Buhler LH, Morel P.Management of gastrointestinal stromal tumours: from diagnosis to treatment . Swiss Med Wkly. 2004;134:145-153.
DeMatteo RP , Lewis JJ, Leung D., Mudan SS, Woodruff JM, Brennan MFTwo hundred gastrointestinal stromal tumors-recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
19.
Tran T., Davila JA, El-Serag HBThe epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992-2000. Am J Gastroenterol . 2005;100:162-168.
20.
Perez EA, Livingstone AS, Franceschi D., et al. Current incidence and outcomes of gastrointestinal mesenchymnal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623-629.
21.
Nilsson B., Bumming P., Meis-Klindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in Western Sweden. Cancer. 2005;103:821-829.
22.
Tryggvason G., Gislason HG, Magnusson MK, Jonasson JGGastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathological risk stratification study. Int J Cancer. 2005 ;117:289-293.
23.
Goettsch WG , Bos SD, Breekveldt-Postma N., Casparie M., Herings RMC, Hogendoorn PCW.Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868-2872.
24.
Steigen SE, Eide TJTrends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS . 2006;114:192-200.
25.
Ahmed I., Welch NT, Parsons SLGastrointestinal stromal tumours (GIST)-17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol. ( 2007), doi:10.1016/j.ejso.2007.01.006.
26.
Chan KH, Chan CW, Chow WH, et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006;12:2223-2228.
27.
Calgary Health Region. http://www.ozcan.ca/chr_map/ . Accessed April 30, 2007.
28.
Calgary Health Region Website. http://www.calgaryhealthregion.ca//hocr/influ/demo/demo.htm . Accessed April 30, 2007.
29.
Statistics Canada Website. http://www.statcan.ca/english/concepts/health . Accessed April 30, 2007.
30.
Connolly EM , Gaffney E., Reynolds JVGastrointestinal stromal tumors. Br J Surg. 2003;90:1178-1186.
31.
Andersson J. , Sihto H., Meis-Kindblom JM, Joensuu H., Nupponen N., Kindblom LGNF-1 associated gastrointestinal stromal tumors have unique clinical, phenotypic and genotypic characteristics. Am J Surg Pathol. 2005;29:1170-1176.
32.
Carney JA, Sheps SG, Go VL, Gordon H.The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma, and pulmonary chondroma. N Engl J Med. 1977 ;296:1517-1518.
33.
Langer C., Gunawan B., Schüler P., Huber W., Füzesi L., Becker H.Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br J Surg. 2003;90:332-339.
34.
Eisenburg BL , Judson I.Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2003;11: 465-475.
35.
Demetri GD, von Mehren M., Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
36.
van Oosterom AT, Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase 1 study. Lancet. 2001;358:1421-1423.
37.
De Silva MVC , Reid R.Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis, and targeted cancer therapy with imatinib. Pathol Oncol Res. 2003;9:13-19.
38.
Goodman VL, Rock EP, Dagher R., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma . Clin Cancer Res. 2007;13:1367-1373.
39.
Blay JY, Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors- report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16:566-578.
